Risperidone-associated diabetes mellitus: a pharmacovigilance study.
about
Selection of atypical antipsychotics for the management of schizophrenia.Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.Blood lactate levels in patients receiving first- or second- generation antipsychotics.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youthRelationship of atypical antipsychotics with development of diabetes mellitus.Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?Pharmacological treatment strategies for schizophrenia.Safety and tolerability of emerging pharmacological treatments for bipolar disorder.Emerging treatments for bipolar disorder: safety and adverse effect profiles.Association between antipsychotic drugs and diabetes.Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Medical co-morbidity risk factors and barriers to care for people with schizophrenia.The metabolic effects of antipsychotic medications.Cardiovascular effects of antipsychotics.Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.Weighing in: emergent diabetes mellitus and second-generation antipsychotics.Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.Atypical antipsychotics and diabetic ketoacidosis: a review.Belgian consensus on metabolic problems associated with atypical antipsychotics.Olanzapine induced biochemical and histopathological changes after its chronic administration in rats.Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication: Literature Review.Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists.Pharmacovigilance in the 21st century: new systematic tools for an old problem.
P2860
Q31037993-F8276DF4-6139-414B-905B-C32409A57697Q33256430-8639F65A-C510-42ED-AB5C-9DA24FAEF0DEQ34595255-DB41C39F-EC7B-41B8-9B8E-AA02FA3AB862Q34613859-CF9C9F68-CD8F-4B3F-B7AA-3546B1FBF253Q34623350-465F26E3-B299-4DC5-983F-42A8D143036BQ35128405-0A57B069-17C4-47DD-98B0-C7EA3B2231C4Q35591014-21B84D36-4B2C-4C48-A5B6-4B6B93C78B0BQ36040749-9CCDE30B-B5AF-4A3D-988C-89A480F205E8Q36107179-94C3A7D8-F61E-4875-A09F-94DB84BDB8D0Q36199036-9EF0C8CA-31DF-4EA9-A9B1-BEACB36F479AQ36364980-C4ED3D21-9BE1-493B-AFB4-EB50421E00DFQ36382695-7576D003-B982-4CD9-A723-6080659CCA92Q36474147-99CADEC6-5562-416F-AF38-D47B6A04AE2FQ36546664-AF1D62E8-60DE-4D07-B153-316B0E5EBA16Q36577856-B9AA1A33-CFC5-477C-98B9-547017D62E3AQ36870063-72543C77-4664-461E-9C68-784224FFA9A3Q36893286-10A72932-5AC7-4033-BC87-16FB25724672Q36929179-0B3A51E4-2DB9-4B43-BE68-3266118D4224Q36929181-01F19012-5E95-4310-824B-7EA56EC9CAFCQ37060706-543FE443-D9EC-457E-ACD4-1111E00228A2Q38076320-2986ABB0-B611-4E6B-A02F-608B18E50499Q38220364-3AE5BA91-B080-4DA5-AF4B-4CC47C150D2FQ41663843-0424FA8B-915F-400C-BC07-AFD88CA385B8Q42358277-24D0DDEE-A185-4F41-814D-B2DC8CA04AA0Q44387572-144C5E13-9868-491C-9DE1-268F73FCF4F0Q45087202-6BC9208D-860E-44DE-9687-93DD54326456
P2860
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
@ast
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
@en
type
label
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
@ast
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
@en
prefLabel
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
@ast
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
@en
P2093
P2860
P1433
P1476
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
@en
P2093
Bruce S Schneider
Elizabeth A Koller
James T Cross
P Murali Doraiswamy
P2860
P304
P356
10.1592/PHCO.23.6.735.32178
P407
P577
2003-06-01T00:00:00Z